Key Highlights
- $190 million in Series A and B financings led by top investors.
- MAR001 targets ANGPTL4 to lower remnant cholesterol and improve metabolic function.
- Innovative pipeline addressing key unaddressed drivers of cardiometabolic diseases.
Source: Business Wire
Notable Quotes
- “Marea aims to transform the way cardiometabolic diseases are treated by leveraging large-scale human genetics and expertise in adipose function and biology to pursue genetically validated targets focusing on central – but unaddressed – drivers of cardiometabolic disease risk.” — Josh Lehrer, M.D., M.Phil., FACC, CEO at Marea Therapeutics
- “With initial clinical validation, world-class scientific founders and investors, and an experienced board and leadership team, Marea is poised to become a premier cardiometabolic disease company.” — Jeffrey Tong, Ph.D., Board Member and Partner at Third Rock Ventures
- “MAR001 has the potential to provide unique benefit to these patients by correcting the underlying adipose dysfunction leading to both elevated remnant cholesterol and metabolic dysfunction.” — Ethan J. Weiss, M.D., Co-founder and Chief Scientific Officer at Marea Therapeutics
- “In a Phase 1 trial, a single dose of MAR001 significantly lowered remnant cholesterol levels and improved metabolic biomarkers. We are very excited about this compound’s potential. Led by renowned experts in genetics and cardiometabolic diseases, Marea is well positioned to advance MAR001 and other pipeline programs, potentially unlocking a new era in cardiovascular care.” — Maha Katabi, Ph.D., General Partner at Sofinnova Investments
SoHC's Take
Marea Therapeutics is making significant strides in the field of cardiometabolic disease treatment with its innovative approach and robust financial backing. The focus on genetically validated targets and adipose function presents a promising frontier for addressing unaddressed drivers of cardiometabolic risk. The successful Phase 1 results of MAR001 and its progression to Phase 2 highlight the potential impact of Marea’s pipeline on millions of patients worldwide. The combination of a strong leadership team, strategic investments, and a clear scientific vision positions Marea Therapeutics as a potential leader in the next generation of cardiometabolic disease treatments.
